[go: up one dir, main page]

FI20011109L - Bis-indolyylisukkiini-imidijohdannaiset ja niiden valmistus - Google Patents

Bis-indolyylisukkiini-imidijohdannaiset ja niiden valmistus Download PDF

Info

Publication number
FI20011109L
FI20011109L FI20011109A FI20011109A FI20011109L FI 20011109 L FI20011109 L FI 20011109L FI 20011109 A FI20011109 A FI 20011109A FI 20011109 A FI20011109 A FI 20011109A FI 20011109 L FI20011109 L FI 20011109L
Authority
FI
Finland
Prior art keywords
indolyl
bis
preparation
succinimide derivatives
succinimide
Prior art date
Application number
FI20011109A
Other languages
English (en)
Swedish (sv)
Other versions
FI20011109A7 (fi
Inventor
Jr William Francis Heath
Michael Robert Jirousek
Iii John Hampton Mcdonald
Christopher John Rito
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI20011109L publication Critical patent/FI20011109L/fi
Publication of FI20011109A7 publication Critical patent/FI20011109A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI20011109A 1993-12-07 2001-05-28 Bis-indolyylisukkiini-imidijohdannaiset ja niiden valmistus FI20011109A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US31697394A 1994-10-03 1994-10-03

Publications (2)

Publication Number Publication Date
FI20011109L true FI20011109L (fi) 2001-05-28
FI20011109A7 FI20011109A7 (fi) 2001-05-29

Family

ID=26859318

Family Applications (3)

Application Number Title Priority Date Filing Date
FI945706A FI108138B (fi) 1993-12-07 1994-12-02 Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-[(N,N'-1,1')-substituoitu alkyleeni)-bis(3,3'-indolyyli)]-1H-pyrroli-2,5-dionijohdannaisten valmistamiseksi
FI20000516A FI20000516A7 (fi) 1993-12-07 2000-03-07 Bis-indolyylimaleimidijohdannaiset ja niiden valmistus
FI20011109A FI20011109A7 (fi) 1993-12-07 2001-05-28 Bis-indolyylisukkiini-imidijohdannaiset ja niiden valmistus

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FI945706A FI108138B (fi) 1993-12-07 1994-12-02 Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-[(N,N'-1,1')-substituoitu alkyleeni)-bis(3,3'-indolyyli)]-1H-pyrroli-2,5-dionijohdannaisten valmistamiseksi
FI20000516A FI20000516A7 (fi) 1993-12-07 2000-03-07 Bis-indolyylimaleimidijohdannaiset ja niiden valmistus

Country Status (30)

Country Link
US (1) US5698578A (fi)
EP (1) EP0657458B1 (fi)
JP (2) JP3581731B2 (fi)
KR (1) KR100340159B1 (fi)
CN (2) CN1050844C (fi)
AT (1) ATE204579T1 (fi)
AU (1) AU687909B2 (fi)
BR (1) BR9404831A (fi)
CA (1) CA2137203C (fi)
CO (1) CO4340622A1 (fi)
CY (1) CY2413B1 (fi)
CZ (1) CZ291950B6 (fi)
DE (1) DE69428025T2 (fi)
DK (1) DK0657458T3 (fi)
ES (1) ES2162843T3 (fi)
FI (3) FI108138B (fi)
GR (1) GR3037087T3 (fi)
HU (1) HU219709B (fi)
IL (1) IL111850A (fi)
MY (1) MY125587A (fi)
NO (1) NO308798B1 (fi)
NZ (1) NZ270048A (fi)
PE (1) PE49195A1 (fi)
PL (1) PL182124B1 (fi)
PT (1) PT657458E (fi)
RU (1) RU2147304C1 (fi)
SG (1) SG63570A1 (fi)
TW (1) TW425397B (fi)
UA (1) UA44690C2 (fi)
YU (1) YU49200B (fi)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
TW371661B (en) * 1995-11-20 1999-10-11 Lilly Co Eli Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
BR9611724A (pt) * 1995-11-20 1999-06-01 Lilly Co Eli Inibidor de quinase c de proteína
JP3258334B2 (ja) * 1996-03-20 2002-02-18 イーライ・リリー・アンド・カンパニー インドリルマレイミドの合成
PL329851A1 (en) 1996-05-01 1999-04-12 Lilly Co Eli Treatment of diseases associated with vegf
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
IL126762A0 (en) * 1996-05-01 1999-08-17 Lilly Co Eli Halo-substituted protein kinase c inhibitors
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
CN1231607A (zh) * 1996-08-30 1999-10-13 伊莱利利公司 利用pkg抑制剂来生产治疗与hiv感染相关的中枢神经系统疾病的药物的用途
AU4250697A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
EP1061062B1 (en) 1998-01-30 2009-02-18 Daiso Co., Ltd. Process for producing butanetriol derivatives
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
WO1999047522A1 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
AU2002227371B2 (en) * 2000-12-08 2007-05-10 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
ATE352312T1 (de) * 2001-12-29 2007-02-15 Novo Nordisk As Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
DE602004025569D1 (de) 2003-06-18 2010-04-01 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
CA2533861A1 (en) 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines
ES2303218T3 (es) * 2004-01-19 2008-08-01 Novartis Ag Derivados de indolilmaleimida.
KR20070011379A (ko) * 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
CA2645289A1 (en) 2006-03-10 2007-09-20 Janssen Pharmaceutica, N.V. Pyridine-containing macroheterocylic compounds as kinase inhibitors
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
RU2441000C2 (ru) * 2009-11-27 2012-01-27 Общество с ограниченной ответственностью "Молекулярные Технологии" 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
MX2012011341A (es) 2010-03-30 2012-11-12 Novartis Ag Inhibidores de pkc para el tratamiento de linfoma de celulas-b que tenga señalizacion activa cronica de receptores de celulas-b.
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
DK2925366T3 (en) 2012-11-29 2018-06-06 Novartis Ag PHARMACEUTICAL COMBINATIONS
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
LT3636649T (lt) 2014-01-24 2024-04-10 Turning Point Therapeutics, Inc. Diarilo makrociklai kaip proteinkinazių moduliatoriai
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
SMT202400213T1 (it) 2015-07-06 2024-07-09 Turning Point Therapeutics Inc Polimorfo di diaril macrociclo
ES2818528T3 (es) * 2015-07-21 2021-04-13 Turning Point Therapeutics Inc Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
EP3658148B1 (en) 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
MX2020006490A (es) 2017-12-19 2020-08-17 Turning Point Therapeutics Inc Compuestos macrociclicos para tratar enfermedades.
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof
EP4654966A1 (en) * 2023-01-27 2025-12-03 Mellicell, Inc. Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
WO2024220957A1 (en) * 2023-04-21 2024-10-24 4M Therapeutics Inc. Polymorphs of n-desmethyl ruboxistaurin and salts thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
FR2614022B1 (fr) * 1987-04-15 1989-12-01 Roussel Uclaf Nouveaux derives 17-aza de 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et ces compositions les renfermant
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
IL94274A0 (en) * 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
CZ213693A3 (en) * 1991-04-11 1994-05-18 Schering Corp Diindolepyrrolbenzodiazocines, process of their preparation and use, and a pharmaceutical mixture based thereon
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
AU7918894A (en) 1995-06-15
MY125587A (en) 2006-08-30
NO308798B1 (no) 2000-10-30
TW425397B (en) 2001-03-11
HK1013827A1 (en) 1999-09-10
CZ291950B6 (cs) 2003-06-18
RU94042922A (ru) 1996-12-27
FI20000516A7 (fi) 2000-03-07
FI945706A0 (fi) 1994-12-02
NZ270048A (en) 1996-11-26
CN1111247A (zh) 1995-11-08
US5698578A (en) 1997-12-16
CN1220266A (zh) 1999-06-23
HUT71130A (en) 1995-11-28
BR9404831A (pt) 1995-08-08
EP0657458A1 (en) 1995-06-14
CZ301894A3 (en) 1995-06-14
JP2004269543A (ja) 2004-09-30
ATE204579T1 (de) 2001-09-15
FI945706A7 (fi) 1995-06-08
PL182124B1 (pl) 2001-11-30
NO944643D0 (no) 1994-12-02
FI108138B (fi) 2001-11-30
FI20011109A7 (fi) 2001-05-29
KR100340159B1 (ko) 2002-11-23
IL111850A (en) 2002-11-10
CY2413B1 (en) 2004-11-12
HU219709B (hu) 2001-06-28
YU70494A (sh) 1997-03-07
RU2147304C1 (ru) 2000-04-10
JP3581731B2 (ja) 2004-10-27
AU687909B2 (en) 1998-03-05
YU49200B (sh) 2004-09-03
CN1050844C (zh) 2000-03-29
UA44690C2 (uk) 2002-03-15
DK0657458T3 (da) 2001-10-29
PT657458E (pt) 2002-02-28
JPH07215977A (ja) 1995-08-15
DE69428025T2 (de) 2002-05-29
ES2162843T3 (es) 2002-01-16
GR3037087T3 (en) 2002-01-31
KR950018010A (ko) 1995-07-22
CA2137203C (en) 2006-11-28
IL111850A0 (en) 1995-03-15
HU9403468D0 (en) 1995-02-28
CA2137203A1 (en) 1995-06-08
CO4340622A1 (es) 1996-07-30
NO944643L (no) 1995-06-08
SG63570A1 (en) 1999-03-30
EP0657458B1 (en) 2001-08-22
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
CN1055089C (zh) 2000-08-02
DE69428025D1 (de) 2001-09-27

Similar Documents

Publication Publication Date Title
FI20011109A7 (fi) Bis-indolyylisukkiini-imidijohdannaiset ja niiden valmistus
FI941137A7 (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI961599A7 (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
FI935074A7 (fi) Uusia tiopyranopyrrolijohdannaisia ja niiden valmistus
FI953666A7 (fi) Hetersykliset yhdisteet ja niiden valmistus ja käyttö
FI954131L (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
FI945900A7 (fi) Bentseenisulfonamidijohdokset ja menetelmä näiden valmistamiseksi
FI935072A7 (fi) Uudet perhydroisoindolit ja niiden valmistus
FI914826A7 (fi) Kinatsoliinijohdokset ja niiden valmistus
FI954130A7 (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
FI945281A7 (fi) Heterosykliset yhdisteet, niiden valmistus ja käyttö
FI924747A7 (fi) PEG-imidaatteja ja niiden proteiinijohdannaisia
FI953919A7 (fi) Pyrrolydeenimetyylijohdannaiset ja menetelmä niiden valmistamiseksi
FI935887L (fi) Tiatzolidiinidionijohdannaiset, niiden valmistus ja käyttö
FI935728L (fi) Substituoituja 4-fenyylipyridoneja ja 4-fenyyli-2-alkoksipyridiinejä
FI943313A7 (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
FI902597A7 (fi) Bentsosykloalkaanijohdannaiset ja niiden valmistus
FI944713L (fi) 4-difenyylimetyylipiperidiinijohdannaisia ja menetelmä niiden valmistamiseksi
FI906425A7 (fi) Kinatsoliinijohdokset ja niiden valmistaminen
FI942294A7 (fi) Bentsopyraanijohdannaiset ja niiden käyttö
FI954229L (fi) Heterosykliset yhdisteet, niiden käyttö ja valmistus
FI961977L (fi) N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö
FI955679L (fi) Piperidiinijohdannaisia, niiden valmistus ja käyttö
FI944040A7 (fi) Laktolijohdannaiset, niiden valmistus ja käyttö
FI944728L (fi) Uudet perhydroisoindolijohdannaiset ja niiden valmistus